Devimistat

Generic Name: Devimistat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈O_₂S_₂

CAS Number: 95809-78-2

Unique Ingredient Identifier: E76113IR49

Background: Devimistat (CPI-613) has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.

Clinical Trials

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: 6,8-Bis(benzylthio)octanoic Acid
Drug: Docetaxel
Other: Pharmacological Study

First Posted Date: 2017-12-12

Last Posted Date: 2018-08-01

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT03370159

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Phase 1

Completed

Conditions: Granulocytic Sarcoma
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: 6,8-Bis(benzylthio)octanoic Acid
Drug: Cytarabine
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2015-06-29

Last Posted Date: 2024-04-30

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 49

Registration Number: NCT02484391

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: 6,8-Bis(benzylthio)octanoic Acid
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride

First Posted Date: 2015-06-16

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT02472626

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Signet Ring Adenocarcinoma of the Colon
Stage IIIB Colon Cancer
Stage IIIC Colon Cancer
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Rectum
Stage IIIA Rectal Cancer
Stage IVA Colon Cancer
Recurrent Colon Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-09-05

Last Posted Date: 2023-08-07

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 19

Registration Number: NCT02232152

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: B-cell Adult Acute Lymphoblastic Leukemia
B-cell Chronic Lymphocytic Leukemia
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Mycosis Fungoides/Sezary Syndrome
Intraocular Lymphoma

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: bendamustine hydrochloride
Biological: rituximab
Other: laboratory biomarker analysis

First Posted Date: 2014-06-20

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 1

Registration Number: NCT02168907

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Adult Lymphocyte Predominant Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
T-cell Large Granular Lymphocyte Leukemia
Adult Nasal Type Extranodal NK/T-cell Lymphoma
T-cell Adult Acute Lymphoblastic Leukemia
Noncutaneous Extranodal Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Adult Mixed Cellularity Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: bendamustine hydrochloride

First Posted Date: 2014-06-20

Last Posted Date: 2024-02-13

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 16

Registration Number: NCT02168140

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 1

Completed

Conditions: Recurrent Small Cell Lung Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid

First Posted Date: 2013-08-29

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 15

Registration Number: NCT01931787

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

Phase 2

Terminated

Conditions: Previously Treated Myelodysplastic Syndromes

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid

First Posted Date: 2013-07-18

Last Posted Date: 2024-10-17

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 12

Registration Number: NCT01902381

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid

First Posted Date: 2013-04-25

Last Posted Date: 2018-12-27

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 10

Registration Number: NCT01839981

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: irinotecan hydrochloride
Drug: fluorouracil
Other: laboratory biomarker analysis

First Posted Date: 2013-04-18

Last Posted Date: 2023-07-12

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 21

Registration Number: NCT01835041

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy